Baricent 2 mg is an oral tablet containing Baricitinib, developed by Incepta Pharmaceuticals Ltd. in Bangladesh. It is primarily indicated for the treatment of moderate to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.